Related Experiment Video

Updated: May 6, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

2.6K

Barriers to Medication Adherence and Mild Cognitive Impairment Among African Americans with Persistently Uncontrolled

Sunidhi Singh1, Joanna Bryan Ringel2, Elizabeth Baquero2

  • 1Weill Cornell Medicine, New York, NY, USA.

Journal of General Internal Medicine
|May 4, 2026
PubMed
Abstract

Insights

Increased medication adherence barriers may indicate mild cognitive impairment (MCI). Identifying these barriers can help detect MCI earlier in patients with uncontrolled hypertension.

Area of Science:

  • Gerontology
  • Neurology
  • Public Health

Background:

  • Mild cognitive impairment (MCI) often goes undetected, potentially leading to medication nonadherence.
  • Investigating the link between adherence barriers and MCI is crucial for early detection and intervention.

Purpose of the Study:

  • To determine if an increased number of reported medication adherence barriers is associated with a higher likelihood of mild cognitive impairment (MCI).

Main Methods:

  • A count of medication adherence barriers (0, 1, 2, ≥3) was developed.
  • The study analyzed the association between the number of barriers and the odds of MCI in 1,279 African American participants with uncontrolled hypertension from rural primary care practices.

Main Results:

  • Participants reporting two or more barriers had significantly higher adjusted odds of MCI (OR=2.40).
  • Those reporting three or more barriers showed even greater odds of MCI (OR=3.80).
  • A significant trend (p<0.001) indicated increasing odds of MCI with an increasing number of reported barriers.

Conclusions:

  • Reported barriers to medication adherence may serve as an early indicator for mild cognitive impairment (MCI).
  • This finding highlights the potential for using adherence data in primary care settings to identify individuals who may benefit from cognitive screening.
Keywords:
cognitive impairmenthypertensionmedication adherence

More Related Videos

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.0K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
400
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
450
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
891